Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alterity Therapeutics Ltd. ( (AU:ATH) ) just unveiled an announcement.
Alterity Therapeutics Ltd. has announced topline data from a Phase 2 study of ATH434, a treatment for Multiple System Atrophy (MSA), presented at the American Academy of Neurology Annual Meeting in 2025. The study was a randomized, double-blind, placebo-controlled trial, indicating a significant step in the company’s research efforts, potentially impacting its position in the neurology field and offering new hope for stakeholders involved in MSA treatment development.
More about Alterity Therapeutics Ltd.
Average Trading Volume: 100
Technical Sentiment Signal: Strong Buy
Current Market Cap: $38.3M
For detailed information about ATH stock, go to TipRanks’ Stock Analysis page.